Clinical trials: Group 2 Pulmonary Hypertension
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Pulmonary Arterial Hypertension
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.
- Trial name
- NCT03884465
- Testing
- Inhaled dry powder treprostinil (LIQ861)
- Where
- 3 sites in France, Germany
- Volunteers
- 15 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Artery Hypertension
A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension
Pulmonary hypertension Group 2 (PH 2) associated with left-sided heart disease is relatively common, is associated with a poor prognosis, and unfortunately there are no proven medical treatments beyond attempts at correcting the…
- Trial name
- NCT02684786
- Testing
- reserpine, stellate ganglion block, lidocaine
- Where
- United States
- Sponsor
- Mayo Clinic
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C…
- Trial name
- NCT01728220
- Testing
- Inhaled NO delivered via INOpulse DS-C Device
- Where
- 43 sites in United States
- Volunteers
- 159 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Artery Hypertension
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.
- Trial name
- NCT04456998
- Testing
- GB002 (seralutinib), Generic Dry Powder Inhaler
- Where
- 63 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Heart Failure, Pulmonary Hypertension
Rivet PVS Therapy in Group 2 PH-HFpEF Canada
This clinical investigation is a prospective, multicenter, non-randomized, open-label, Early Feasibility Study to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with…
- Trial name
- NCT05332873
- Testing
- Rivet Shunt
- Where
- Canada
- Sponsor
- NXT Biomedical
Pulmonary Hypertension
Acute Assessment of the Aria CV System in Patients With WHO Groups 2 and 3 Pulmonary Hypertension
This study is a prospective, non-randomized, two arm, single-center acute feasibility study assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH patients.
- Trial name
- NCT05001711
- Testing
- Aria CV Acute PH System
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Aria CV, Inc
Group 2 Pulmonary Hypertension, CpcPH
Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension
The goal of this clinical trial is to test the efficacy of tadalafil in patients with group II pulmonary hypertension with CpcPH with elevated pulmonary vascular resistance (PVR equals or more than 4 WU).
- Trial name
- NCT06350773
- Testing
- tadalafil 20 mg then 40 mg if tolerated
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Beni-Suef University
Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).
- Conditions
- Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH, HFmrEF, HFpEF
- Trial name
- NCT07147114
- Testing
- Combination therapy, Monotherapy
- Where
- 15 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Gachon University Gil Medical Center
Hypertension, Pulmonary
This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure in the pulmonary blood vessels due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary…
- Trial name
- ATMOS (NCT03754660)
- Testing
- BAY1237592
- Where
- 8 sites in Austria, Czechia and 2 more
- Volunteers
- 38 people
- Sponsor
- Bayer
Atrial Fibrillation, Pulmonary Hypertension
Pulmonary Artery Denervation in Patients With Atrial Fibrillation and Group 2 of Pulmonary Hypertension
The goal of the study is to compare efficacy and safety of the pulmonary artery denervation procedure combined with atrial fibrillation ablation versus atrial fibrillation ablation alone in patients with paroxysmal and persistent…
- Trial name
- PADN+AF (NCT05856461)
- Testing
- Pulmonary vein isolation, Pulmonary artery denervation
- Where
- Russia
- Volunteers
- 116 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Pulmonary Hypertension Associated With HFpEF
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular…
- Trial name
- LEVEL-2 (NCT07288398)
- Testing
- TNX-103
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 540 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Arterial Hypertension
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to evaluate the safety and effectiveness of an investigational/experimental drug called AIR001. To test the effectiveness, the study will evaluate how AIR001 affects the blood vessels in the lungs and…
- Trial name
- NCT01725256
- Testing
- AIR001 (sodium nitrite inhalation solution)
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- Aires Pharmaceuticals, Inc.
Pulmonary Hypertension, Familial Persistent, of the Newborn
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.
- Trial name
- NCT01720524
- Testing
- iv sildenafil
- Where
- 42 sites in United States, Belgium and 10 more
- Volunteers
- 59 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Heart Failure, Pulmonary Hypertension
Rivet PVS Therapy in Group 2 PH-HFpEF
This clinical investigation is a prospective, multicenter, non-randomized, open-label, Early Feasibility Study to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with…
- Trial name
- NCT05205265
- Testing
- Rivet Shunt
- Where
- 3 sites in United States
- Sponsor
- NXT Biomedical
Pulmonary Arterial Hypertension
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH.
- Trial name
- ViTAL-PH (NCT06846554)
- Testing
- APL-9796
- Where
- 6 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Apollo Therapeutics Ltd
Pulmonary Arterial Hypertension
Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
The AIR001-CS05 study evaluated the safety and efficacy (effectiveness) of AIR001 over 16 weeks in subjects who have PAH. The purpose of the AIR001-CS06 study is to evaluate the intermediate / long-term safety of AIR001 in…
- Trial name
- NCT01725269
- Testing
- AIR001
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 17 people
- Sponsor
- Aires Pharmaceuticals, Inc.
Pulmonary Arterial Hypertension
Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Ubenimex is being developed for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) to improve exercise capacity and delay clinical worsening.
- Trial name
- LIBERTY2 (NCT02736149)
- Testing
- ubenimex
- Where
- 28 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Eiger BioPharmaceuticals
Group 2 Pulmonary Hypertension, Heart Failure
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
This early feasibility study is intended to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension
- Trial name
- PreVail-PH2 (NCT06052072)
- Testing
- Gradient Denervation System
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gradient Denervation Technologies